Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients


Creative Commons License

Kirkpantur A., Balci M., Gurbuz O. A. , Afsar B. , Canbakan B., Akdemir R., ...Daha Fazla

NEPHROLOGY DIALYSIS TRANSPLANTATION, cilt.26, sa.4, ss.1346-1354, 2011 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 26 Konu: 4
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1093/ndt/gfq539
  • Dergi Adı: NEPHROLOGY DIALYSIS TRANSPLANTATION
  • Sayfa Sayıları: ss.1346-1354

Özet

Background. Fibroblast growth factor-23 (FGF-23) is a phosphorus-regulating substance. Circulating FGF-23 levels increase markedly in dialysis patients and are independently associated with increased risk of mortality. Given the fact that cardiovascular disease is the leading cause of death in dialysis patients, the aim of this study was to test if elevated FGF-23 levels might be associated with left ventricular mass index (LVMI) and left ventricular index of myocardial performance (MPI) in maintenance haemodialysis patients.